Entrectinib Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::ROS1 | Non-Small Cell Lung Cancer | Entrectinib |